Aquestive Therapeutics, Inc. (AQST)
AQST moved a median of 0.00% 30 minutes after news, and -0.12% by the close. How AQST actually reacts to news — the realized, point-in-time move the market made, measured across 725 labeled events over the last three years with zero look-ahead.
AQST’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 44% | 721 |
| 30-min | 0.00% | 47% | 723 |
| 60-min | +0.12% | 52% | 723 |
| to close | -0.12% | 48% | 716 |
| Middle 50% of AQST reactions | -0.94% to +0.75% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 725 |
Half of all Aquestive Therapeutics, Inc. news events land between -0.94% and +0.75% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How AQST reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 16 | +0.26% | 56% | -0.17% |
| Rating reiterations | 64 | -0.54% | 36% | +0.39% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how AQST ranks against every other measured name →
That’s how AQST usually reacts — get an email when it moves on news →Email me when AQST moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to AQST's baseline. Nothing else.
Recent AQST events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027 | Press release | GlobeNewswire | -0.86% | -12.88% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.48% | -3.22% | |
| Form 8-K Aquestive Therapeutics, For: Oct 15 | SEC filing · Form 8-K | SEC EDGAR | -0.86% | -12.88% | |
| Form 8-K Aquestive Therapeutics, For: Oct 13 | SEC filing · Form 8-K | SEC EDGAR | -0.88% | -1.07% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aquestive Therapeutics, Inc. (AQST) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | -0.00% | -1.48% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | +0.06% | +0.84% | |
| Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.54% | +2.15% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.22% | +1.21% | |
| Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly | Press release | GlobeNewswire | +0.21% | -0.64% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.00% | +0.97% | |
| Form 8-K Aquestive Therapeutics, For: Sep 29 | SEC filing · Form 8-K | SEC EDGAR | +0.21% | -0.64% | |
| Form 8-K Aquestive Therapeutics, For: Sep 23 | SEC filing · Form 8-K | SEC EDGAR | +0.21% | -2.90% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.42% | +2.01% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | +0.40% | -0.50% | |
| Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film | Press release | GlobeNewswire | -1.20% | -6.80% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.52% | -2.31% | |
| Form 8-K Aquestive Therapeutics, For: Sep 14 | SEC filing · Form 8-K | SEC EDGAR | -1.20% | -6.80% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.00% | -0.29% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | -2.69% | -3.34% | |
| Aquestive Therapeutics to Participate in Upcoming September Investor Conferences | Press release | GlobeNewswire | -0.19% | +1.75% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aquestive Therapeutics, Inc. (AQST) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | -0.19% | -0.66% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | -0.50% | +2.82% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.40% | +0.69% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | -0.64% | +2.78% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aquestive Therapeutics, Inc. (AQST) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | -0.11% | +1.47% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.14% | -0.57% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +1.66% | +1.66% | |
| Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | +4.49% | +0.47% | |
| Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.11% | -5.37% | |
| Form 10-Q Aquestive Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +4.49% | +0.47% | |
| Form 8-K Aquestive Therapeutics, For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | +4.49% | +0.47% | |
| Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film | Press release | GlobeNewswire | +0.69% | — | |
| Form 8-K Aquestive Therapeutics, For: Aug 10 | SEC filing · Form 8-K | SEC EDGAR | +0.69% | — | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.26% | +2.48% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aquestive Therapeutics, Inc. (AQST) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | +0.00% | +0.13% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | +0.14% | +2.43% | |
| Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.41% | +1.09% | |
| Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET | Press release | GlobeNewswire | -0.13% | -3.74% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.13% | +2.46% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | +4.16% | +3.32% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | -0.64% | -3.70% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aquestive Therapeutics, Inc. (AQST) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | -0.12% | -0.49% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.24% | -4.25% | |
| Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.73% | -0.73% | |
| Form EFFECT Aquestive Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | +0.58% | -1.85% | |
| Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism | Press release | GlobeNewswire | -1.28% | +0.23% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.94% | +1.29% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | -0.35% | -1.30% | |
| Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.48% | -0.48% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | -1.72% | -4.59% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the AQST section they belong to.
Where else AQST is measured.
AQST earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| INSYS THERAPEUTICS (INSY) | 731 | +0.00% | 50% |
| Myovant Sciences Ltd. Common Shares (MYOV) | 728 | 0.00% | 49% |
| RETROPHIN INC (RTRX) | 723 | +0.06% | 52% |
| IsoRay, Inc. (DE) (ISR) | 722 | -0.01% | 45% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Aquestive Therapeutics, Inc.'s median reaction calculated?
Every labeled AQST news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 725 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 47% of AQST's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does AQST's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.